SAM
ANIP icon

SEB Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

SEB Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Buy
56,333
+18,219
+48% +$1.46M 0.02% 483
2026
Q1 		$2.93M Buy
+38,114
New +$2.97M 0.01% 534

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SEB Asset Management's ANIP Position: Q2 2026 in Review

SEB Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 48% in Q2 2026, buying an estimated $1.46M and bringing the position to 56,333 shares worth $4.66M. The position accounts for 0.02% of the portfolio, ranked #483.

SEB Asset Management first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • SEB Asset Management held 56,333 shares of ANI Pharmaceuticals worth $4.66M as of Q2 2026.
  • SEB Asset Management bought 18,219 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • ANI Pharmaceuticals made up 0.02% of SEB Asset Management's portfolio in Q2 2026, its #483 holding.
  • SEB Asset Management first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.